The European Pharmaceutical Wholesale Industry: - phagro

More documents

Recommendations

Info

The European Pharmaceutical Wholesale Industry 2 Approach and Methodology Purpose of the Study The purpose of the study was to highlight the role of pharmaceutical wholesalers within the pharmaceutical sector, as the tasks performed by them are often overlooked in political and public debate. Thus, the study predominantly aims to draw a comprehensive picture of the pharmaceutical wholesale industry. The analysis focused on the following questions: � What is the pharmaceutical wholesale industry’s position in the European pharmaceutical sector and how can it be represented by core indicators? � How did the wholesale industry evolve since the 1990s and what were the most influencing factors shaping the industry? � What is the wholesale industry’s contribution to overall economic performance, that is, how much value added and jobs are created by pharmaceutical wholesalers? � What services are provided by pharmaceutical wholesalers and how do they create added value for customers up and down the pharmaceutical supply chain and for the patients? � What driving factors and trends are likely to change pharmaceutical distribution in the years to come? Data Source The data for the analysis are exploited on a European, a national and a companybased level. Thus, the paper covers all countries of the European Union, except Cyprus, Malta and Slovakia. These three countries have been excluded from the analysis, since in Cyprus and Malta pharmaceuticals are distributed by agents (no full-line wholesalers) and Slovakia, where due to the fact that an association representing exclusively pharmaceutical full-line wholesalers is only in creation, the basis for reliable data is not sufficient. Hence, the majority of the data refer to EU- 22. As the markets not observed are rather small, the results of the analysis claim to be representative for all 25 countries of the EU. Special focus (by way of an indepth analysis) was laid on the presentation of the biggest European pharmaceutical wholesale markets, France, Germany, Italy, the Netherlands, Spain and the UK (in alphabetic order). In addition Austria became part of this in-depth analysis. The data necessary for the macroeconomic analysis was obtained from different sources. First, a questionnaire was directed to the national pharmaceutical wholesalers’ associations in Austria, France, Germany, Italy, the Netherlands, Spain and 3 IPF Institute for Pharmaeconomic Research
The European Pharmaceutical Wholesale Industry the UK. Second, data were provided by the European Association of Pharmaceutical Full-line Wholesalers (GIRP), consisting of GIRP’s annual statistics. The data obtained by the questionnaire and the GIRP-file were supplemented by EURO- STAT, WHO, IMS Health data and further internet and literature research. In addition, the results of expert talks complete the information provided. The following notes have to be considered when reading the study: � The analysis made focus on the year 2004. But as some of the macroeconomic investigations are based on EUROSTAT data, which are only available until 2002 at latest, these analyses have a deviant time horizon. In addition, some data for the “new” EU-member states are not provided by EUROSTAT, often limiting the results presented to the EU-15. � The results presented relate to full-line wholesalers operating on a national and regional level. � The number of employees in pharmaceutical wholesaling as displayed in this study is only an extrapolation, because comprehensive data on employment are only available for GIRP-members and not for non-members. No data on employment could have been obtained for the “new” EU-members. � The wholesale industry’s sales are computed on a pharmacy purchase price level before rebates and without value added tax. In addition to the macroeconomic data, company-based data were used to highlight processes and services provided by pharmaceutical wholesalers. The inputs for these analyses were obtained by a second inquiry directed at full-line wholesalers in Europe. The company-data are presented on an aggregated level, so none of the statements in this report can be attributed to any of these companies individually. Course of the Analysis In order to answer the questions above, the following analyses have been conducted: � A general overview of the pharmaceutical sector in Europe is given at the beginning of the report. � The structure of the branch and its development are described by the core indicators market structure, sales and employment with respect to factors influencing these indicators. � The macroeconomic impact of the pharmaceutical wholesale industry was calculated for the 7 countries which were part of the in-depth analysis. The analy- IPF Institute for Pharmaeconomic Research 4
Page 1: ��
Page 4 and 5: Contents a The European Pharmaceuti
Page 6 and 7: Figures c The European Pharmaceutic
Page 8 and 9: The European Pharmaceutical Wholesa
Page 10 and 11: III The European Pharmaceutical Who
Page 12 and 13: V The European Pharmaceutical Whole
Page 14 and 15: VII The European Pharmaceutical Who
Page 18 and 19: 1 Introduction 1 The European Pharm
Page 22 and 23: 5 The European Pharmaceutical Whole
Page 28 and 29: 11 The European Pharmaceutical Whol
Page 40 and 41: 23 75 74 73 72 71 70 The European P
Page 60 and 61: 43 40 35 30 25 20 15 10 5 0 The Eur
Page 70 and 71:
The European Pharmaceutical Wholesa
Page 72 and 73:
55 The European Pharmaceutical Whol
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
9 Bibliography 69 The European Phar
show all

The European Pharmaceutical Wholesale Industry: - phagro

Create successful ePaper yourself

Delete template?

Save as template?